|Bid||9.40 x 0|
|Ask||9.41 x 0|
|Day's Range||9.11 - 9.92|
|52 Week Range||7.97 - 32.95|
|Beta (3Y Monthly)||4.07|
|PE Ratio (TTM)||6.99|
|Earnings Date||Nov. 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.84|
Top cannabis players have lost 75% in market value over the last year. Here's why investors can expect weakness to continue in the short-term.
Marijuana stock Cronos Group (TSX:CRON)(NASDAQ:CRON) is undergoing massive transformation. You need to know these coming changes.
TORONTO — Cannabis company Cronos Group Inc. reported a profit in its third quarter, boosted by an $835-million gain in derivative liabilities, as revenue grew to $12.7 million.The company says its net profit amounted to $788 million or 53 cents per diluted share for the quarter ended Sept. 30. That compared with a loss of $7.3 million or four cents per share in the same quarter last year.Cronos says its adjusted earnings before interest, taxes, depreciation and amoritization amounted to a loss of $23.9 million in its most recent quarter compared with a loss of $3.2 million a year ago.Revenue was up from $3.8 million in the same quarter last year and up from $10.2 million in the second quarter of 2019.Analysts had expected Cronos to report $14.1 million in revenue for its third quarter, according to financial markets data firm Refinitiv.Cronos says it sold 3,142 kilograms of cannabis in Canada in the quarter, up from 514 kilograms in the third quarter last year and 1,584 kilograms in the second quarter of 2019.This report by The Canadian Press was first published Nov. 12, 2019.Companies in this story: (TSX:CRON) The Canadian Press
Here’s what you need to know about Cronos Group’s (TSX:CRON)(NASDAQ:CRON) latest quarterly financial results.
Closed Redwood U.S. Hemp-Based Products Platform and Cronos Fermentation Facility Acquisitions Announced the launch PEACE+™, A New Hemp-Derived U.S. Brand Advanced Operational.
After parting ways with Canadian cannabis giant Canopy Growth, Bruce Linton is joining the board of U.S. multi-state operator Vireo Health.
Aphria’s stock price has risen 8.9% since reporting its Q1 earnings on October 15. The cannabis sector's weakness offset some of these gains.
Cannabis company Cronos Group has expanded its presence in the US cannabidiol market through a tie-up with tobacco company Altria Group.
Canopy Growth (CGC) (WEED) and Cronos Group (CRON) are set to release their earnings next week. The cannabis sector has been on a roller coaster this year.
Cantor Fitzgerald is predicting “green days ahead” for the battered shares that have struggled to find their footing since Canada legalized recreational pot more than a year ago.
Tilray and Cronos stocks are trading at 52-week lows. Here we compare various metrics between the two stocks to analyze which is a better buy at the current price.
For Aurora Cannabis (ACB), Canaccord lowered its target price from 13.50 Canadian dollars to 8.00 Canadian dollars with a “speculative buy” rating.
Canopy Growth (CGC), Aurora Cannabis (ACB), and Cronos Group (CRON) closed at year-to-date discounts of 33.43%, 32.97%, and 30%, respectively, yesterday.
When Altria posted its earnings yesterday, things looked positive. However, after news about Juul Labs, MO stock lost momentum and closed 2.6% lower.
If you're new to cannabis investing, don't take unnecessary risks. Stocks like Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) and HEXO Corp. (TSX:HEXO)(NYSE:HEXO) are all you need.
Media reports indicate that Angela Merkel’s party may consider legalizing cannabis in Germany. Medical marijuana has been legal in Germany since 2017.
On Friday, Aurora Cannabis (ACB) traded at 4.99 Canadian dollars, down 14.3% for the month. Of the 16 analysts that follow ACB, 43.8% favor a “buy” rating.
The cannabis market is expected to hit $100 billion in sales by 2030, but the true upside could be much larger. If you want to capitalize, stick with Cronos Group Inc (TSX:CRON)(NYSE:CRON).
Cronos Group Inc. (CRON.TO) (CRON.TO) (“Cronos Group” or the “Company”) today noted the separately announced closing of the AUD$20 million initial public offering of Cronos Australia Limited (“Cronos Australia”). Under the offering, Cronos Australia issued 40 million new shares at an offering price of AUD$0.50 per share (the “Cronos Australia IPO”). Cronos Australia expects to start trading on the Australian Securities Exchange on a deferred settlement basis on November 7, 2019.
Pot stocks like Cronos Group Inc (TSX:CRON)(NYSE:CRON) and Green Organic Dutchman (TSX:TGOD) are cheap, but be careful about which companies you trust with your money.